CUDA

• Description :

  CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively[1]. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease[2].

• UNSPSC :

  12352211

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Epoxide Hydrolase; PPAR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/cuda.html

• Purity :

  99.83

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1CCCCC1)NCCCCCCCCCCCC(O)=O

• Molecular Formula :

  C19H36N2O3

• Molecular Weight :

  340.50

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Morisseau C, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002 May 1;63 (9) :1599-608.|[2]Fang X, et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005 Jul;314 (1) :260-70.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PPARα

• CAS Number :

  [479413-68-8]